Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Ono Pharmaceutical Co., Ltd.
  6. Summary
    4528   JP3197600004

ONO PHARMACEUTICAL CO., LTD.

(4528)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
2527.5 2493.5 2486 2430 2512.5 Last
784400 1164300 2058300 1344900 1765700 Volume
+0.18% -1.35% -0.30% -2.25% +3.40% Change
Estimated financial data (e)
Sales 2021 313 B 2 816 M 2 816 M
Net income 2021 75 339 M 678 M 678 M
Net cash position 2021 108 B 975 M 975 M
P/E ratio 2021 16,7x
Yield 2021 1,99%
Sales 2022 352 B 3 169 M 3 169 M
Net income 2022 85 799 M 773 M 773 M
Net cash position 2022 101 B 906 M 906 M
P/E ratio 2022 14,6x
Yield 2022 2,15%
Capitalization 1 254 B 11 320 M 11 293 M
EV / Sales 2021 3,66x
EV / Sales 2022 3,28x
Nbr of Employees 3 607
Free-Float 76,6%
More Financials
Company
ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals. 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
Ratings of Ono Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ONO PHARMACEUTICAL CO., LTD.
06/09Japanese shares rise, Eisai drops after 2 days of limit-up gains
RE
06/02Japan shares rally as reopening hopes boosts travel, real estate firms
RE
06/01Japan shares rally as reopening hopes boosts travel, real estate firms
RE
04/28ONO PHARMACEUTICAL  : Announcement of New Office Establishment of U.S. Subsidiar..
AQ
04/22ONO PHARMACEUTICAL  : Helsinn Announces the Launch of Adlumiz (anamorelin) for t..
AQ
04/21PRESS RELEASE : Helsinn Announces the Launch of Adlumiz(R) (anamorelin) for the ..
DJ
04/15ONO PHARMACEUTICAL  : Submits Supplemental Application for Approval for Opdivo (..
AQ
04/09ONO PHARMACEUTICAL  : Bristol Myers Squibb Announces Opdivo (nivolumab) plus Che..
AQ
04/05ONO PHARMACEUTICAL  : Announcement on Changes of Members of the Board of Directo..
AQ
03/31BRISTOL MYERS SQUIBB  : Ono Pharmaceutical Co., Ltd - European Medicines Agency ..
AQ
03/30ONO PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
03/29ONO PHARMACEUTICAL  : Joins the University of California Drug Discovery Consorti..
AQ
03/29ONO PHARMACEUTICAL  : Received 'Osaka Governor's Award' of the Osaka Stop Global..
AQ
03/24ONO PHARMACEUTICAL  : and Seikagaku Announce a Manufacturing and Marketing Appro..
AQ
03/02ONO PHARMACEUTICAL  : Entered License Agreement with PeptiDream Inc. on Automate..
AQ
More news
News in other languages on ONO PHARMACEUTICAL CO., LTD.
06/02Nikkei 225 : Borsa Tokyo chiude in rialzo, speranze riapertura spingono titol..
2020Borsa Tokyo riparte dopo stop tecnico, Nikkei in calo su notizia Trump positi..
2019DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 18.07.2019 - 15.15 Uhr
2019Bayer hofft auf neues Einsatzfeld für Krebsmedikament Stivarga
2018TOKYO STOCK EXCHANGE : Tokyo finit en hausse de 0,10%
More news
Chart ONO PHARMACEUTICAL CO., LTD.
Duration : Period :
Ono Pharmaceutical Co., Ltd. Technical Analysis Chart | 4528 | JP3197600004 | MarketScreener
Technical analysis trends ONO PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 2 512,50 JPY
Average target price 3 315,38 JPY
Spread / Average Target 32,0%
EPS Revisions
Managers and Directors
NameTitle
Gyo Sagara President & Representative Director
Toichi Takino Managing Executive Officer & GM-Research
Yutaka Kato Independent Outside Director
Jun Kurihara Independent Outside Director
Masao Nomura Independent Outside Director
Sector and Competitors